论文部分内容阅读
为探索氟阿糖腺苷和瘤可宁联合用药治疗慢性淋巴细胞白血病(CLL)的剂量安全性,1988年美国西南肿瘤组进行了Ⅰ期研究,为临床治疗提供用药的剂量和疗程安排。本组包括21例进展性、复发性或难治性中度或高危状态的B细胞CLL,根据联合用药的剂量分为Ⅰ、Ⅱ和Ⅲ组,瘤可宁的用量分别为20、15和15mg/m~2,口服,第1天;氟阿糖腺苷的用
In order to explore the dose-safety of combination therapy of fluoral adenosine and tacrine in the treatment of chronic lymphocytic leukemia (CLL), the United States of America Southwest Oncology Group conducted a phase I study in 1988 to provide the dosage and course of treatment for clinical treatment. This group includes 21 cases of progressive, recurrent or refractory moderate or high-risk state of B cell CLL, according to the combination of the dose divided into Ⅰ, Ⅱ and Ⅲ group, the tumor Ning dosage were 20,15 and 15mg / m ~ 2, orally, the first day; the use of fluroside adenosine